Directed new share issue in Xspary Pharma AB (SE) — SEK 122 million

Carnegie acted as joint bookrunner in the directed new share issue of 1,675,162 new shares at a subscription price of SEK 73 per share. Xspray Pharma AB is a pharmaceutical development company with several product candidates in clinical development. Xspray employs a patent protected technology platform to develop improved and generic versions of already marketed drugs, primarily protein kinase inhibitors (PKIs) for targeted cancer treatment. December 2019.